Tert-Butyl 4-Oxohexahydrocyclopenta[C]Pyrrole-2(1H)-Carboxylate

Development of an oral PI3Kδ inhibitor for relapsed follicular lymphoma necessitated a four-step telescoped sequence starting from tert-butyl 4-oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate. The Boc-protected amino alcohol precursor was generated by a chelation-controlled Grignard addition—cyclopentylmagnesium bromide, 1.05 eq, in anhydrous THF at −30 °C—yielding the tertiary carbinol with a diastereomeric ratio exceeding 14:1 after an aqueous quench monitored by FTIR for complete consumption of the ketone carbonyl stretch at 1740 cm⁻¹. Subsequent hydrochloride salt formation utilized anhydrous HCl gas sparged through a 2 µm sintered frit into isopropyl acetate at a jacket temperature of −8 °C to −3 °C. This narrow thermal window proved critical: excursions above 0 °C promoted acid-catalysed dehydration of the nascent tertiary alcohol, generating a conjugated diene impurity that co-crystallised with the API downstream. The HCl salt was filtered under nitrogen pressure on a 24-inch PTFE-lined Sparkler filter, reslurried with methyl tert-butyl ether (3 volumes), and dried at 40 °C under vacuum until residual isopropyl acetate fell below 200 ppm by headspace GC. The liberated amine was telescoped into a reductive amination with a proprietary benzoxaborole aldehyde SG-2019.43: sodium triacetoxyborohydride (1.35 eq) in tetrahydrofuran adjusted to apparent pH 5.2–5.5 by addition of glacial acetic acid, stirred at 22 ± 2 °C for 18 hours. Process-scale campaigns executed in a 100 L glass-lined steel reactor equipped with a triple-pitch retreat-blade impeller and a Coriolis mass-flow controller for HCl gas delivery consistently met intermediate specifications: purity ≥99.0% by HPLC at 210 nm, total unspecified impurities ≤0.10%, residual palladium below 5 ppm via ICP-MS (USP 〈232〉), and water content ≤0.05% by Karl Fischer. The final Active Pharmaceutical Ingredient crystallised as a dihydrate polymorph designated Form A; per ICH Q11, the regulatory starting material designation was anchored at the azabicycle entrance point, with a comprehensive control strategy traceable to both the ketone and the carbamate integrity assays.

What Limits the Reductive Amination Scope When the Ketone Is α to a Bridgehead?

Reductive amination of tert-butyl 4-oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate with primary amines must reconcile the competitive reduction of the ketone to the corresponding alcohol while preserving the acid-labile Boc group. Sodium cyanoborohydride (1.1–1.3 eq) in methanol buffered with acetic acid to a measured apparent pH of 4.8–5.3 delivers the desired N-alkyl product with selectivity ratios of approximately 7:1 over alcohol formation when the amine nucleophile is a sterically unencumbered aniline bearing an electron-withdrawing para-substituent. Bulkier benzylamine derivatives shift the selectivity unfavourably, often requiring a switch to sodium triacetoxyborohydride (1.5 eq) in dichloromethane containing 0.5% v/v acetic acid to maintain a ketone-to-alcohol ratio above 9:1. Scale-up batches conducted in 1,000 L Hastelloy reactors revealed an exotherm of 12–15 °C upon addition of the hydride reagent; dose rate was consequently restricted to 0.18 kg/min under a jacket setpoint of −5 °C to hold the internal temperature below 20 °C. Workup involved quenching into 5% w/w aqueous citric acid at 5 °C—sufficient to protonate excess amine but insufficient to trigger substantial Boc cleavage (<2% after 30 min exposure). The crude base was isolated by extraction into MTBE, washed with 8% w/v sodium bicarbonate to neutral pH, and polished through a 0.5 kg silica gel plug. Terminal product specifications for the reductive amination intermediate destined for a Factor XIa inhibitor programme demanded chromatographic purity ≥98.5% and chiral purity ≥99.5% ee as measured on a Chiralpak IA-3 column with hexane:isopropanol 80:20 mobile phase (ASTM D8143-17 compliant instrument qualification). Residual EtOAc and CH₂Cl₂ were controlled to ≤300 ppm and ≤50 ppm respectively per USP 〈467〉 Procedure A, and the water content was held below 0.1% to avoid hydrolysis of the Boc group during subsequent steps.

Fully protected chiral pyrrolidine-based organocatalysts of the MacMillan-type imidazolidinone family have been synthesised from this scaffold by sequential stereoselective reduction and N-alkylation. tert-Butyl 4-oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate was dissolved in freshly distilled THF (0.3 M) and cooled to −40 °C under argon. (+)-Diisopinocampheylchloroborane ((+)-DIP-Cl, 1.25 eq, titrated to 1.0 M in hexanes) was introduced via a syringe pump over 90 minutes, keeping the internal temperature below −35 °C. Conversion, tracked by disappearance of the ketone C=O band with in-line ReactIR, routinely exceeded 98% within 4 hours. The secondary alcohol was obtained in >99% ee after oxidative workup with 3 M sodium hydroxide/30% hydrogen peroxide at 0 °C. The Boc group was subsequently removed using anhydrous 4 M HCl in 1,4-dioxane (5 volumes, 25 °C, 2 hours) to yield the amino alcohol hydrochloride, which was engaged in a reductive alkylation with acetone and sodium triacetoxyborohydride to forge the imidazolidinone core. Manufacturing at a 50 kg scale of the Boc-intermediate required strict control of moisture (≤50 ppm in the THF by Karl Fischer) to prevent catalyst quenching, and the entire cryogenic operation was performed in a 400 L jacketed stirred-tank reactor with a secondary liquid-nitrogen cooling loop. The enantiomeric purity specification for the organocatalyst precursor was anchored to USP 〈621〉 System Suitability, and the final imidazolidinone catalyst was supplied under a CEP (Certificate of Suitability to the Monographs of the European Pharmacopoeia) as a 98.0% min. purity GMP-grade reagent used in an asymmetric Diels-Alder route generating the bicyclic core of a commercial antiviral agent.

Spirocyclopropanation Partner in Voxelotor-Analogue Hemoglobin Modulators

The ketone functionality embedded in the hexahydrocyclopenta[c]pyrrole bicycle serves as a robust handle for Corey-Chaykovsky spirocyclopropanation, enabling access to conformationally constrained amines that mimic the central phenoxyacetic acid motif of voxelotor. In a representative campaign, the substrate (1.0 eq) was dissolved in DMSO (6 volumes) containing powdered sodium hydride (60% dispersion in mineral oil, 1.4 eq), and trimethylsulfonium iodide (1.5 eq) was added portionwise at 15–20 °C over 45 minutes. The slurry was aged for 12 hours at ambient temperature, ensuring complete diastereoselective cyclopropanation with a diastereomeric ratio exceeding 25:1 by ¹H NMR analysis of the crude mixture. The Boc group remained intact throughout, with cleavage below 0.3% under these conditions. The product spirocyclopropane-Boc-amine was extracted with methyl tert-butyl ether, washed sequentially with 10% w/v sodium thiosulfate and brine, and crystallised from n-heptane:isopropanol (95:5 v/v) to deliver a white crystalline solid with a typical melting endotherm onset at 122.7 °C by DSC (10 K/min, nitrogen purge). Intermediate release for the downstream Pd-catalysed Buchwald-Hartwig amination required palladium content below 2 ppm—achieved through a charcoal filtration step—and residual iodide below 15 ppm by ion chromatography. The resulting spirocyclic amine, after Boc deprotection with trifluoroacetic acid in dichloromethane (1:1 v/v, 0 °C, 1 hour), was directly engaged in urea formation with the requisite aryl isocyanate to furnish haemoglobin oxygen-affinity modulators evaluated in a Phase I trial for sickle cell disease. The entire process was operated under an ICH Q7-compliant quality system, with intermediate hold-time validated for 72 hours at 2–8 °C prior to the final coupling stage.

When a Proline Isostere Must Resist Exopeptidase Cleavage in Subcutaneous Depot Formulations

Peptide-based gonadotropin-releasing hormone antagonists designed for once-monthly subcutaneous depots require a non-proteinogenic amino acid at the N-terminus to block aminopeptidase degradation. The Boc-protected bicyclic ketone was reduced to the corresponding secondary amine with borane-dimethylsulfide complex (1.8 eq) in THF at reflux, then immediately reprotected with Fmoc-OSu (1.15 eq) in the presence of N,N-diisopropylethylamine (2.2 eq) to yield Fmoc-4-hydroxyhexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate. This Fmoc-amino alcohol was elaborated on a 200 mmol scale into the mixed anhydride with isobutyl chloroformate (1.05 eq) and N-methylmorpholine (1.3 eq) in DMF at −15 °C, then coupled to a Wang resin-tethered octapeptide under conditions rigorously anhydrous to avoid premature diketopiperazine formation. Resin loading was determined by Fmoc-UV titration (USP 〈1041〉 surrogate) to be 0.62–0.68 mmol/g. After global TFA cleavage, the crude peptide bearing the hexahydrocyclopenta[c]pyrrole-derived turn-inducing unit exhibited a β-hairpin conformation by circular dichroism (minimum at 218 nm) with enhanced stability against leucine aminopeptidase: <5% cleavage after 24-hour incubation at 37 °C in fortified human plasma, compared to >90% degradation of the natural proline-containing analog. Purity requirements for preclinical peptide batches followed Ph.Eur. 01/2024:1740 guidelines for synthetic peptides, with the key intermediate Fmoc-amino alcohol controlled to ≥98.0% by non-aqueous titration and optical rotation [α]ᴅ²⁰ = +34.5 ± 2° (c=1, MeOH). Hazard assessment of the mixed anhydride formation focused on the thermal stability of the isobutyl chloroformate reaction, which was evaluated by differential scanning calorimetry; onset of decomposition occurred at 128 °C with an adiabatic time-to-maximum-rate of >24 hours per the Stoessel protocol, classifying the operation as TMRad Class 5 and permitting standard batch processing.

Fragment-based screening cascades against the SARS-CoV-2 main protease (M^pro, 3CL^pro) identified a hit cluster containing the hexahydrocyclopenta[c]pyrrole core, which was prioritised owing to its high aqueous solubility and ligand efficiency. tert-Butyl 4-oxohexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate itself, after Boc deprotection and acylation with a panel of heteroaryl carboxylic acids, generated a 96-member library assessed via surface plasmon resonance (Biacore T200, CM5 chip, immobilised M^pro at ~8,000 RU). Fragments were screened at a single concentration of 500 µM in running buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.05% Tween-20, and 2% DMSO. The bicyclic scaffold consistently produced dissociation constants (K_D) in the range of 120–850 µM, with on-rates (k_a) exceeding 10⁴ M⁻¹s⁻¹, indicative of rapid fragment engagement at the catalytic dyad. For the crystallographic fragment growth campaign, the ketone was derivatised via oxime formation with O-(tert-butyldimethylsilyl)hydroxylamine to mask polarity while retaining a hydrogen bond acceptor; co-crystal structures solved at 1.75 Å resolution confirmed water-mediated contacts with Glu166. All fragment submissions to the Diamond Light Source–University of Oxford fragment consortium adhered to a purity standard of ≥99.5% (qNMR, DMSO-d₆ internal standard) and contained less than 0.05% residual Pd or Cu by ICP-OES. The compound is classified as a non-PGI under FDA 21 CFR 210.3 and was transported under a USMCA Certificate of Origin for research use only, with a 24-month retest dating when stored at −20 °C under argon.